

Date: 7 June 2018

Sydney, Australia

ASX: NOX

Noxopharm Limited

ABN 50 608 966 123

Registered Office and Operational Office: Suite 3, Level 4 828 Pacific Highway Gordon NSW 2072 Australia

Board of Directors Mr Peter Marks Chairman

Non-Executive Director

Dr Graham Kelly Chief Executive Officer Managing Director

Dr lan Dixon Non-Executive Director

ASX Limited 20 Bridge Street SYDNEY NSW 2000

NOXOPHARM CORPORATE PRESENTATION FOR PUBLIC BRIEFING

Sydney, 7 June 2018: Noxopharm (ASX: NOX) today conducts the first of a series of Public Briefings and duly releases the official corporate presentation to be used.

The presentation addresses the Company's 3-pronged clinical trial strategy for its experimental anti-cancer drug, NOX66, embracing the CEP, DARRT and LuPIN programs and outlining for each program its current status, the anticipated news flow, and future clinical strategy.

The details of today's briefing are:

Time: 10.30 am Thursday June 7

Place: Sofitel Sydney Wentworth Hotel, 61-101 Phillip St.

To view this corporate presentation please visit the Noxopharm website (www.noxopharm.com) Home Page – Latest News

About NOX66

NOX66 is a novel lipophilic formulation of the experimental anti-cancer drug, idronoxil. Idronoxil is a triple-acting drug: (i) cytotoxic to cancer cells; (ii) blocks DNA repair; (iii) activates innate immune cells including natural killer (NK) cells. In conjunction with cytotoxic chemotherapy drug therapy (CEP program), it is being used to augment the cytotoxic effect of chemotherapy and to reverse resistance to chemotherapy drugs. In conjunction with radiotherapy (DARRT program), it is being used to augment both the direct and indirect (abscopal) effects of external beam radiotherapy and stereotactic body radiotherapy. In conjunction with intravenous radionuclide therapy (LuPIN program), it is being used to augment the anti-cancer activity of this therapy.

About Noxopharm

Noxopharm is an Australian drug development company with offices in Sydney and Hong Kong. The Company has a primary focus on the development of drugs to sensitise cancer cells to radiotherapy and chemotherapy. NOX66 is the first pipeline product, with later generation drug candidates under development.

Investor & Corporate Enquiries: Prue Kelly M: 0459 022 445 E: <u>info@noxopharm.com</u> Company Secretary: David Franks T: +61 2 9299 9690 E: dfranks@fa.com.au

www.noxopharm.com

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.





A clinical-stage oncology drug company developing a disruptive technology for the treatment of solid cancers by radiotherapy and chemotherapy

Open Briefing June 2018




Unique dual-acting anti-cancer drug

NOX66 Idronoxil (lipophilic form)


inhibits DNA repair

inhibits PARP-1, topoisomerases 1 and 2



promotes anti-tumour immunity

Increases NK (natural killer) cell activity







3-horse race

- Risk mitigation
- Identify optimal route to market
- Expand post-registration markets











Chemotherapy Enhancement Program

Objective:

- To enable salvage chemotherapy in patients with late-stage, resistant cancers
- NOX66 in combination with low-dose cytotoxic chemotherapy
- Aim to deliver a <u>meaningful anti-cancer effect</u> in <u>at least 50% patients</u> in <u>a well tolerated way</u>





CEP-1 Phase 1 Sighting study

Details:

- 19 patients; late-stage, metastatic cancer; no remaining standard Rx options
- Breast, lung, ovarian, prostate
- 14-day NOX66 run-in
- ✤ 6 cycles; each cycle = NOX66 (7 days) + carboplatin (1 day) each month
- 3 patients withdrew voluntarily; 1 carboplatin sensitivity; 1 sudden death; 4 death from progressive disease; 2 non-evaluable





Outcomes

Safety:

- 5 Grade 3 toxicities, all resolved. All other toxicities mild.
- No toxicity associated with NOX66

Efficacy:

	Partial response	Stable disease	Disease progression	<u>Total</u>
3 cycles	0	12	2	14
6 cycles	1	5	4	10*

* 12 started: 1 withdrew: 1 sudden death

CEP

CEP-2

- Phase 2
- NOX66 Dosage: 800 mg

Platinum based therapy. Which drug?

- Carboplatin
- Cisplatin
- Oxaliplatin
- Which cancer type(s)? What end-points?
- Protocol design
 - Q3 Meet with Advisory Board
 - Q4 Final protocol
 - Early-2019 Study opens


Direct and Abscopal Response to Radio-Therapy






External Beam RT or Stereotactic Body RT


- Patients with multiple (>3) tumours
- Irradiate 1-2 tumours (5 days)
- NOX66 14 days
- Scan + 6 weeks and 12 weeks




Direct and Abscopal Response to Radio-Therapy












Direct and Abscopal Response to Radio-Therapy



Abscopal Response







DARRT-1

Details:

- Phase 1b multi-national study
- 24 patients; metastatic castrate-resistant prostate cancer
- NOX66 + External beam RT
- RT (5-10 days) A NOX66 (duration of RT + 7 days)
- 4 Cohorts:
 - 400 mg NOX66 (4 patients) completed
 - 800 mg NOX66 (4 patients) completed
 - 1200 mg NOX66 (4 patients) enrolled
 - Best NOX66 dose (12 patients)

DARRT-1

SCHEDULE

- ✤ Late-July 2018. Complete treatment and 6-week scans on first 3 cohorts.
 - Independent review of data
 - Select NOX66 dosage
- ✤ Late-Aug 2018. Commence recruitment of Cohort 4.
 - Target complete recruitment of all 24 patients in Q3 2018
 - 12 week review for all patients Q4
 - Study complete Q1 2019

DATA RELEASE

- ✤ Early-July 2018. Presentation at ANZUP
 - Study outline, safety of initial treatment
- ✤ <u>Aug 2018</u>. Release of 6-week data.

Other Studies


DART-2: Solid tumours

- Phase 1b; expanding DARRT-1 research beyond prostate cancer
- Provide guidance on criteria which may suggest better response to NOX66
- Decision point DARRT-1: 12 patient, 6 weeks scan → drive protocol development
- Commence study Q4 2018
- DARRT-3: Phase 2/3 registrational planning
 - Key study for first registration of NOX66
 - Feasibility, country and site identification (global) commence Q3 2018
 - Decision point DARRT-1: 24 patients, 12 week → submission processes begin
 - Commence mid 2019
- Supportive research
 - Further small investigator led research studies
 - Specific patient populations; treatment regimen (e.g. stereotactic RT)


LuPIN

Lutetium-PSMA In Combination With NOX66






THERANOSTICS



LuPIN

Lutetium-PSMA In Combination With NOX66





THERANOSTICS

- Phase 1b study; investigator-initiated; St Vincent's Hospital Sydney
- Late-stage prostate cancer (metastatic castrateresistant disease)
- ¹⁷⁷ Lutetium-PSMA-617
- 6 x monthly intravenous injections of LuPSMA + 10 days NOX66
- 6 patients 400 mg NOX66; 10 patients 800 mg NOX66

LUPIN

Lutetium-PSMA In Combination With NOX66

LuPIN-1

- Recruitment ongoing presentation of trial outline at ASCO 2018
- First 4 patients in 5th cycle of therapy; first key data expected late-2018


Next Steps

- Development of expanded LuPIN study
 - Phase 2 multi-centre, sponsored study
 - Planned commencement early-2019
- Other targeted radionuclides
 - Partnership planning for other targeted therapies
 - Phase 1 studies early-2019

Key metrics



Free float 66.8%	
\$90M	
20 cents	
\$1.58/0.29	
\$0.54M	
AU\$ 11.8 (31 March 2018)	



Disclaimer

- This presentation has been prepared by Noxopharm Limited a company proposed to be listed as [ASX:NOX] (NOX or the Company). It should not be considered as an offer or invitation to subscribe for or purchase any shares in NOX or as an inducement to make an offer or invitation to subscribe for or purchase any shares in NOX. No agreement to subscribe for securities in the NOX will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.
- This presentation is not a prospectus, product disclosure document or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licenced to, and does not provide, financial advice.
- This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.
- Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making. Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.
- Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.



NOXOPHARM



